Share: Facebook Twitter GooglePLus LinkedIn
Activity Provided By:

University Learning Systems

Live Webinar - Opioids, Cannabinoids and Gabapentenoids: Defining the Best Pharmacological Practice Model for the Treatment

Access Activity

Overview / Abstract:

Join us for 3 hours of Live Opioids CME via Zoom Webinar

Opioids, Cannabinoids and Gabapentenoids: Defining the Best Pharmacological Practice Model for the Treatment
At the conclusion of this program, the participant will be able to:
1. Discuss the burden of opioid misuse and abuse on the individual and society. 2. Differentiate addiction, physical dependency, tolerance and hyperalgesia. 3. Describe the similarities and differences in the mechanism of action for opioids, cannabinoids and gabapentenoids. 4. Compare and contrast the current best practice model for the use of opioids, cannabinoids and gabapentenoids in: a) acute postoperative pain; b) chronic low back pain; c) neuropathic pain; d) fibromyalgia; e) end-of-life pain crisis. 5. Describe how to calculate morphine-equivalent dosages (MED). 6. Demonstrate the value of morphine-equivalent dosages (MED) in determining the benefit and safety of opioids in the treatment of pain. 7. Identify typical characteristics of patients who would be identified as "high risk" , "moderate risk" and "low risk" for misusing, abusing or diverting opioids. 8. Describe the best practice model for properly monitoring patients on opioids. 9. Describe how a provider should counsel patients who are started on opioids to minimize the risks of adverse reactions, over-dosage and inappropriate compliance. 10. Identify examples of opioids products that have “abuse-deterrent” technology and be able to recommend to prescribers how these products could be utilized to improve patient and community safety. 11. Compare and contrast the most common cannabinoids found in marijuana with regards to their benefits and risks in managing pain. 12. Compare and contrast the following gabapentenoids with respect to their benefits and risks in managing pain: a) gabapentin (Neurontin); b) Horizant; c) Gralise; and, d) Lyrica. 13. Describe the risks of combining opioids with: a) benzodiazepines; b) alcohol; c) gabapentenoids; and, d) cannabinoids. 14. Describe the role of naloxone in preventing deaths from overdosages. of Pain


Sep 16, 2020


Nurse Practitioner , Pharmacy CPE, Physician CME, Physician Assistant CME


Live / Seminar, Webinar / Webcast / Video



Credits / Hours

0.3 CEU/3 contact hours



Is This Activity Certified for "Live" Credit?


Presenters / Authors / Faculty

Gregory L. Holmquist, Pharm D.
Pain and Palliative Care Pharmacist Specialist, Palliative Care Strategies, Everett, Washington.
Dr. Holmquist has NO financial arrangements with any corporate organization that might have an interest in the subject being presented.

Activity Specialities / Related Topics

Family Medicine, Pain Management, Palliative Care / Hospice, Pharmacology, Primary Care, Substance Abuse / Dependence

Sponsors / Supporters / Grant Providers

University Learning Systems

Keywords / Search Terms

University Learning Systems live webinar, pain, opioids, cme, live cme, live ce, ce, pharmacy ce, pharmacology ce, physician cme, physician assistant cme, nurse practitioner cme, nursing cme, opioid abuse cme, acpe, aafp, Live CE CME Seminar CE CME

LIVE Activity Location Details


Zoom Webinar

Access Activity

RXinsider,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps. RXinsider,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or or within our mobile apps. For complete details, please read the Terms of Service. Site Map.